Methods for treatment of Alzheimer's disease
AssigneeAlphabeta AB
InventorJan Johansson
Life of this patent
Estimating the term…
Abstract
An isolated protein selected from the group consisting of (i) proteins comprising an amino acid sequence having at least 70% identity to the C-terminal domain of lung surfactant protein C precursor (CTproSP-C, “CTC”) from a mammal; and (ii) proteins comprising an amino acid sequence having at least 70% identity to the Brichos domain of CTproSP-C from a mammal, is disclosed for treatment of Alzheimer's disease in a mammal, including man.
Claims17
A method of therapeutically treating or delaying progression of Alzheimer's disease in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of an isolated protein, wherein the isolated protein delays or reduces amyloid fibril formation and aggregation of amyloid β peptide, and wherein the isolated protein is selected from:
- (a) a protein comprising an amino acid sequence having all conserved residues of mammalian C-terminal domain of lung surfactant protein C precursor (CTproSP-C) (SEQ ID NO:
- 11) and having at least 70% identity to the CTproSP-C from human (SEQ ID NO:
- 2), bovine (SEQ ID NO:
- 5), rhesus (SEQ ID NO:
- 6), mouse (SEQ ID NO:
- 7), mink (SEQ ID NO:
- 8), rabbit (SEQ ID NO:
- 9) or rat (SEQ ID NO:
- 10);
- or
- (b) a protein comprising an amino acid sequence having all conserved residues of the Brichos domain of mammalian CTproSP-C (SEQ ID NO:
- 18) and having at least 70% identity to the Brichos domain of CTproSP-C from human (SEQ ID NO:
- 4), bovine (SEQ ID NO:
- 12), rhesus (SEQ ID NO:
- 13), mouse (SEQ ID NO:
- 14), mink (SEQ ID NO:
- 15), rabbit (SEQ ID NO:
- 16) or rat (SEQ ID NO:
- 17).
Dependencies are inferred from the claim text.